Ahrn B, Leguizamo Dimas A, Miossec P, et al
Hindawi Limited Zander M, Madsbad S, Madsen JL, Holst JJ (2002) Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and -cell function in type 2 diabetes: a parallel-group study
Combination with muscle-preserving agents: Companies developing myostatin and activin pathway inhibitors alongside GLP-1RAs are addressing a real unmet need that Novo Nordisk and Eli Lilly are also pursuing but have not yet solved
Nausea and vomiting rates are actually slightly higher with the pill, largely due to the fasting requirement
But her body didn't respond the way she expected
doi: 10.1126/sciadv.adr5051, 100 MinJ